|
Showing 1 - 25 of
64 matches in All Departments
Making your capital work hard has never been more important than
it is today. Investment trusts, often over looked as an investing
vehicle, are a key tool in getting better returns on your money.
The Financial Times Guide to Investment Trusts is your
concise and jargon free introduction to one of the City’s best kept
secrets. It explains how investment trusts differ from unit trusts and
OEICs and explores the pros and cons of investment trusts including
their superior performance. It also helps you identify your investment
objectives, discusses the basic principles of successful investing, and
how to run a trust portfolio.
Whether you are a novice DIY investor or have many years’ experience
and wish to question the experts; the FT Guide to Investment Trusts:
- Provides a detailed overview of what investment trusts are and
how they differ from other funds
- Examines the factors which help to explain the better performance
of trusts – including cheaper fees, discounts and gearing
- Analyses the stepping stones to successful investing
- Shows you how to construct and monitor a trust portfolio
- Highlights the workings of two live and benchmarked portfolios
which John has been sharing with Investor Chronicle readers over the
years.
The subject of smoking and the hormone disorders associated with it
are of relatively recent interest. Its importance increases as the
average age at death of the population increases and many of those
people will have had a lifetime smoking. The book provides
summaries of the present status of research into the effects of
smoking and the apparent protection offered against certain
diseases. Some research workers have suggested ways of predicting
trends of disease patterns such as osteoporetic fractures. Not all
the disorders discussed are adverse effects of smoking and these
have provided impetus for developing non-tobacco methods of disease
prevention. As the smoking population diminishes and the
availability of lower tar brands increases, a reduction in many of
the adverse disorders is expected and will form the basis for
continued monitoring.
|
|